# Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit – Enveric Biosciences
Canonical URL: https://biopharmsignal.com/news/ENVB/enveric-biosciences-announces-participation-in-b-riley-securities-mind-muscle-vi-247d268d
Ticker: ENVB
Company: Enveric Biosciences
Source: Enveric Biosciences
Published: 2026-07-09 00:03 EST
Original Source URL: https://www.enveric.com/news/
## Summary

CAMBRIDGE, Mass. – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological d...

## Article Body
CAMBRIDGE, Mass. – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within the neuropsychiatry sector and the outlook for mental health drug development.

Event Details:

Event:

Mind, Muscle & Vision Summit, Hosted by B. Riley Securities

Agenda:

Neuropsychiatry Fireside Chat

Date & Time:

July 16, 2026, 12:30-12:55 PM EDT

Location:

Abigail Adams Salon A, InterContinental Boston

“We are excited to discuss the current trends in neuropsychiatry and demonstrate how EB-003, a unique neuroplastogen designed to not induce hallucinogenic effects, is positioned to address key challenges in mental health drug development,” said Joseph Tucker, Ph.D., CEO of Enveric. “With encouraging preclinical data driving us steadily toward IND submission and Phase 1 clinical entry, we look forward to sharing our momentum and unique mechanism of action with potential investors and strategic partners at the summit.”

Enveric’s management team will also conduct one-on-one meetings with registered investors throughout the day to discuss the Company’s business strategy, recent corporate achievements, and upcoming clinical milestones.

About Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT 2A and 5-HT 1B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.

For more information, please visit www.enveric.com .

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “proposes,” “budgets,” “explores,” “schedules,” “seeks,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND application to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.

A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260629700344/en/
## Recent Company News
- 2026-07-09 00:03 EST — [Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003 – Enveric Biosciences](https://biopharmsignal.com/news/ENVB/enveric-biosciences-reports-positive-preclinical-results-from-phototoxicity-anal-df7fb40c) — Source: Enveric Biosciences
- 2026-07-09 00:03 EST — [Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003 – Enveric Biosciences](https://biopharmsignal.com/news/ENVB/enveric-biosciences-initiates-investigational-new-drug-ind-enabling-genotoxicity-f8edbc3d) — Source: Enveric Biosciences
- 2026-07-09 00:03 EST — [Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day – Enveric Biosciences](https://biopharmsignal.com/news/ENVB/enveric-biosciences-to-participate-in-the-ubs-3rd-virtual-cns-day-enveric-biosci-50e4be54) — Source: Enveric Biosciences
- 2026-07-09 00:03 EST — [Enveric Biosciences Announces Participation in 2026 BIO International Convention – Enveric Biosciences](https://biopharmsignal.com/news/ENVB/enveric-biosciences-announces-participation-in-2026-bio-international-convention-9148266a) — Source: Enveric Biosciences
- 2026-07-09 00:03 EST — [Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit – Enveric Biosciences](https://biopharmsignal.com/news/ENVB/enveric-biosciences-announces-participation-in-b-riley-securities-mind-muscle-vi-247d268d) — Source: Enveric Biosciences
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)